Drug Profile
Recombinant human serum albumin biosimilar - Ventria Bioscience
Alternative Names: Optibumin; VEN-200Latest Information Update: 07 Jan 2022
Price :
$50
*
At a glance
- Originator Ventria Bioscience
- Class Acute-phase proteins; Albumins; Plasma expanders; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypoalbuminaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Hypoalbuminaemia in USA (Parenteral)
- 04 Mar 2013 Early research in Hypoalbuminaemia in USA (Parenteral)